In:
Cardiology, S. Karger AG, Vol. 144, No. 1-2 ( 2019), p. 27-35
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Elevated plasma homocysteine (Hcy) and high-sensitivity C-reactive protein (hsCRP) levels are independent risk factors for cardiovascular diseases. However, it is unclear whether the coexistence of these conditions accelerates the risk of arterial stiffness. Our study aimed to evaluate the association of combined Hcy and hsCRP with arterial stiffness in Chinese middle-aged adults. 〈 b 〉 〈 i 〉 Material/Methods: 〈 /i 〉 〈 /b 〉 We conducted a 12-year longitudinal study in 220 individuals in Hanzhong, China, from 2005 to 2017. The average age at follow-up was 41.83 ± 3.10 years. Demographic information, medical history, anthropometric measurements, and blood pressure as well as urine and fasting blood samples, including Hcy, hsCRP, and brachial-ankle pulse wave velocity (baPWV) were measured and analyzed. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 BaPWV levels showed a linear growth trend with the increasing of hsCRP ( 〈 i 〉 p 〈 /i 〉 for trend & #x3c;0.01). The ORs in the highest quartile compared to the lowest quartile were 1.985 (95% CI 0.776–5.077; 〈 i 〉 p 〈 /i 〉 = 0.152) and 3.960 (95% CI 1.468–10.684; 〈 i 〉 p 〈 /i 〉 = 0.007) for Hcy and hsCRP, respectively. When Hcy and hsCRP were combined, subjects in both the highest quartile of Hcy and hsCRP (Hcy ≥15.50 μmol/L and hsCRP ≥0.82 μmol/L) had a 12.68-fold increased risk of developing arterial stiffness at the 12-year follow-up compared to those in the lowest quartile of Hcy and hsCRP (Hcy ≤9.91 μmol/L and hsCRP ≤0.19 μmol/L) after adjusting for potential confounders. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 The present study demonstrated that the combination of elevated serum Hcy and hsCRP may contribute to an increased risk of arterial stiffness.
Type of Medium:
Online Resource
ISSN:
0008-6312
,
1421-9751
Language:
English
Publisher:
S. Karger AG
Publication Date:
2019
detail.hit.zdb_id:
1482041-9
Permalink
